ATE483978T1 - Anti-epha2 antikörper als krebsdiagnostikum - Google Patents

Anti-epha2 antikörper als krebsdiagnostikum

Info

Publication number
ATE483978T1
ATE483978T1 AT00955686T AT00955686T ATE483978T1 AT E483978 T1 ATE483978 T1 AT E483978T1 AT 00955686 T AT00955686 T AT 00955686T AT 00955686 T AT00955686 T AT 00955686T AT E483978 T1 ATE483978 T1 AT E483978T1
Authority
AT
Austria
Prior art keywords
epha2
cancer diagnostic
epha2 antibodies
kits
overexpressed
Prior art date
Application number
AT00955686T
Other languages
English (en)
Inventor
Michael Kinch
Nicole Zantek
Katherine Kilpatrick
Original Assignee
Purdue Research Foundation
Glaxo Group Ltd
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Glaxo Group Ltd, Univ North Carolina filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of ATE483978T1 publication Critical patent/ATE483978T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00955686T 1999-08-17 2000-08-17 Anti-epha2 antikörper als krebsdiagnostikum ATE483978T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14925999P 1999-08-17 1999-08-17
PCT/US2000/022669 WO2001012840A2 (en) 1999-08-17 2000-08-17 Anti-epha2 antibodies as a cancer diagnostic

Publications (1)

Publication Number Publication Date
ATE483978T1 true ATE483978T1 (de) 2010-10-15

Family

ID=22529464

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00955686T ATE483978T1 (de) 1999-08-17 2000-08-17 Anti-epha2 antikörper als krebsdiagnostikum

Country Status (8)

Country Link
EP (2) EP2312316A1 (de)
JP (3) JP4948728B2 (de)
AT (1) ATE483978T1 (de)
AU (1) AU785445C (de)
CA (1) CA2382655A1 (de)
DE (1) DE60045075D1 (de)
ES (1) ES2357296T3 (de)
WO (1) WO2001012840A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
CN1441676B (zh) 2000-03-31 2012-08-22 普渡研究基金会 用配体-免疫原缀合物治疗的方法
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2003004529A2 (en) * 2001-07-02 2003-01-16 Licentia Ltd. Ephrin-tie receptor materials and methods
EP2168598A1 (de) * 2001-09-28 2010-03-31 Purdue Research Foundation Verfahren zur Behandlung mit Ligand-Immunogen-Konjugaten
AU2002348854A1 (en) * 2001-11-09 2003-05-19 Neuronova Ab Method of proliferation in neurogenic regions
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
JP4585968B2 (ja) * 2002-05-10 2010-11-24 パーデュー・リサーチ・ファウンデーション ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
ATE525398T1 (de) * 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
US7662770B2 (en) 2002-05-23 2010-02-16 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target
CA2525929A1 (en) 2003-05-13 2004-11-25 Chiron Corporation Methods of modulating metastasis and skeletal related events resulting from metastases
EP1682173A4 (de) * 2003-10-15 2007-10-31 Medimmune Inc Epha2-vakzine auf listeria-basis
EP1778726A4 (de) 2004-08-16 2009-03-18 Medimmune Inc Integrin-antagonisten mit verbesserter antikörperabhängigen zellvermittelter zytotoxizitätsaktivität
CN101155830B (zh) 2005-02-04 2014-06-18 雷文生物技术公司 结合epha2的抗体及其使用方法
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
BRPI0816094A2 (pt) 2007-08-30 2015-03-03 Daiichi Sankyo Co Ltd Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6069806B2 (ja) * 2013-02-13 2017-02-01 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6399013B2 (ja) * 2016-02-18 2018-10-03 トヨタ自動車株式会社 化学蓄熱器の制御装置
JP6729917B2 (ja) * 2016-08-19 2020-07-29 国立大学法人 東京大学 ＥｐｈＡ２ Ｎ末端フラグメント抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69228300T2 (de) 1991-08-22 1999-09-23 Becton Dickinson And Co., Franklin Lakes Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
US5876949A (en) 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same

Also Published As

Publication number Publication date
EP2312316A1 (de) 2011-04-20
AU785445B2 (en) 2007-06-14
EP1210603A2 (de) 2002-06-05
WO2001012840A3 (en) 2001-05-03
AU785445C (en) 2008-01-31
EP1210603B1 (de) 2010-10-06
WO2001012840A2 (en) 2001-02-22
DE60045075D1 (de) 2010-11-18
CA2382655A1 (en) 2001-02-22
JP2003507023A (ja) 2003-02-25
ES2357296T3 (es) 2011-04-25
JP2012103264A (ja) 2012-05-31
AU6784300A (en) 2001-03-13
JP2007291140A (ja) 2007-11-08
JP4948728B2 (ja) 2012-06-06
WO2001012840B1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
ATE483978T1 (de) Anti-epha2 antikörper als krebsdiagnostikum
EP1585966B8 (de) Behandlung von Krebs mit dem anti-ErbB2-Antikörper rhuMAb 2C4
RU2005131842A (ru) Моноклональное антитело и продуцирующая его гибридома
WO2004032842A3 (en) Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
RU2001102598A (ru) Способ ранней диагностики карцином
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
WO2000052204A3 (en) Gene expression in bladder tumors
CA2384579A1 (en) Early cancer tumor marker
WO2005113000A3 (en) Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
Ahmad et al. Antigens, antibodies, and membranous nephropathy: a decade of progress
NZ288235A (en) Monoclonal antibody directed against the receptor tyrosine kinase flt4 and use in diagnosis and therapy
WO2007111875A3 (en) Methods for diagnosing and treating kidney and colorectal cancer
EP0163303A3 (de) Menschliche monoklonale Antikörper gegen Zelloberflächen- oder Innenzellantigene
EP1214447B8 (de) Nachweis des pyruvatkinase-isoenzyms im stuhl
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
CN101042402A (zh) 用于癌症诊断的自身抗体检测
WO1998022825A3 (en) A whole blood/mitogen assay for the early detection of a subject with cancer and kit
DK1907842T3 (da) Identifikation af ikke-småcellede lungecarcinom-tumorer (NSCLC) udtrykkende PDGFR-alfa
WO2005114203A3 (en) Dominant b cell epitopes and methods of making and using thereof
Fang et al. Quantum dots for cancer diagnosis
AU2003255671A1 (en) Anti-aurora-a monoclonal antibody, method for obtaining same, and uses thereof for diagnosing and treating cancers
CA2264963A1 (en) Protein markers for esophageal cancer
WO2003001884A3 (en) Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer
WO2003099104A3 (en) Elisa assay of serum soluble cd22 to assess tumor burden/relapse in subjects with leukemia and lymphoma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties